While primarily used for erectile dysfunction and pulmonary arterial hypertension (PAH), PDE5-induced intracellular cGMP stabilization provides potential therapeutic benefits for hypertension, coronary artery disease (CAD), stroke, chronic kidney disease (CKD), and type 2 diabetes (T2D).3 Soluble guanylate cyclase stimulators (sGCs) directly stimulate sGC independently of NO availability, augmenting cGMP production, and promoting vasodilation. Here, PDE5A is linked to pulmonary arterial hypertension.